Broenshoej, Denmark

Soeren Oestergaard

USPTO Granted Patents = 6 

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 39(Granted Patents)


Company Filing History:


Years Active: 2014-2020

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Soeren Oestergaard: Innovator in PYY Compounds

Introduction

Soeren Oestergaard is a notable inventor based in Broenshoej, Denmark. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of PYY compounds. With a total of 6 patents to his name, Oestergaard's work has implications for medical applications and receptor agonists.

Latest Patents

Oestergaard's latest patents include innovative compounds such as HPYY(1-36) with a beta-homoarginine substitution at position 35. This invention focuses on PYY compounds that are selective Y2 receptor agonists. Additionally, he has developed PYY compounds with tryptophan substitution at position 30, which also serve as selective Y2 receptor agonists. These compounds are accompanied by pharmaceutical compositions that include pharmaceutically acceptable excipients, highlighting their potential medical uses.

Career Highlights

Soeren Oestergaard is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk has allowed him to explore and innovate in the realm of peptide-based therapeutics. Oestergaard's research has contributed to advancements in understanding the role of PYY compounds in medical treatments.

Collaborations

Oestergaard has collaborated with esteemed colleagues such as Birgitte Schjellerup Wulff and Kilian Waldemar Conde Frieboes. These collaborations have fostered a productive environment for research and development in the field of pharmaceutical sciences.

Conclusion

Soeren Oestergaard's contributions to the development of PYY compounds and his innovative patents underscore his role as a significant inventor in the pharmaceutical industry. His work continues to pave the way for advancements in medical applications and receptor-targeted therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…